Natalizumab discontinuation in a Dutch real-world cohort.

Objective: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort.

Methods: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC.

Results: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity.

Conclusions: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.